Lila Hope

    • Zai Lab Enters License and Collaboration Agreement with Blueprint Medicines 

    • I-Mab Enters Global Strategic Partnership With AbbVie for Cancer Treatment 

    • CardioKinetix Completes $50 Million Financing 

    • Adamas Pharmaceuticals Initial Public Offering 

    • Ascendis Pharma closes $124 million IPO 

    • Nexvet Biopharma Closes Initial Public Offering 

    • Cour and Takeda Partner to Treat Celiac Disease 

    • Exelixis and Ipsen Enter into Exclusive Licensing Agreement to Commercialize and Develop Novel Cancer Therapy Cabozantinib in Regions Outside the United States, Canada and Japan 

    • Avidity Biosciences Licensing and Research Collaboration with Eli Lilly 

    • Otsuka $825 Million Collaboration Agreement to Develop Alzheimer's Drug 

    • MyoKardia Collaboration with Sanofi 

    • Portola Pharmaceuticals $140 Million IPO 

    • Rigel Pharmaceuticals License and Supply Agreement with Kissei Pharmaceutical Valued up to $180 Million 

    • Turnstone Biologics License Agreement with AbbVie 

    • Vivo Capital in its Licensing Agreements with Ascendis Pharma 

    • Xyphos Biosciences in its Research Collaboration and License Agreement with Parker Institute for Cancer Immunotherapy 

    • Portola Agrees to Sell to Alexion for $1.41 Billion 

    • Fate Therapeutics Licensing and Platform Collaboration with Janssen Biotech 

    • Zai Lab Product Commercialization Collaboration with Regeneron 

    • Vaxcyte - $288 Million IPO 

    • Genesis MedTech Acquires Drug Device Asset From TriReme Medical 

    • Goldfinch Bio Announces Strategic Collaboration with Gilead 

    • Singapore’s Engine Biosciences Raises $43 Million to Decipher Genetic Codes for New Medicines 

    • Lulu’s – $92 Million IPO 

    • Fate Therapeutics Expansion of Collaboration with ONO Pharmaceutical